Radiopharmaceutical manufacturer International Isotopes last month posted its fiscal 1998 results (end-December). The Denton, TX, firm reported revenues of $2 million for the year, a dramatic increase over 1997’s $136,000. The company attributed the
Radiopharmaceutical manufacturer International Isotopes last month posted its fiscal 1998 results (end-December). The Denton, TX, firm reported revenues of $2 million for the year, a dramatic increase over 1997s $136,000. The company attributed the increase to its International Isotopes Idaho subsidiarys product sales, as well as income from development contracts. The companys net loss for the year was $5.5 million, compared with the previous years $4.4 million loss.
In other news, the firm last month formed a joint venture with GammaPlus, an Austin, TX-based subsidiary of Lucas Medical Associates that operates short-lived radiopharmaceutical manufacturing centers. The joint venture will be called GammaPlus DFW, and will manufacture and distribute PET radiopharmaceuticals, including fluorodeoxyglucose F-18 (FDG). GammaPlus DFW will produce FDG with International Isotopes cyclotron, and expects to begin distributing the isotope within the next few months, according to Carl Seidel, president and CEO of International Isotopes. Distribution will be primarily to hospitals and clinics in the Dallas/Fort Worth area, Seidel said.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.